Facets (new session)
Description
Metadata
Settings
owl:sameAs
Inference Rule:
b3s
b3sifp
dbprdf-label
facets
http://dbpedia.org/resource/inference/rules/dbpedia#
http://dbpedia.org/resource/inference/rules/opencyc#
http://dbpedia.org/resource/inference/rules/umbel#
http://dbpedia.org/resource/inference/rules/yago#
http://dbpedia.org/schema/property_rules#
http://www.ontologyportal.org/inference/rules/SUMO#
http://www.ontologyportal.org/inference/rules/WordNet#
http://www.w3.org/2002/07/owl#
ldp
oplweb
skos-trans
virtrdf-label
None
About:
Antigen-specific oncolytic MV-based tumor vaccines through presentation of selected tumor-associated antigens on infected cells or virus-like particles
Goto
Sponge
NotDistinct
Permalink
An Entity of Type :
schema:ScholarlyArticle
, within Data Space :
covidontheweb.inria.fr
associated with source
document(s)
Type:
Academic Article
research paper
schema:ScholarlyArticle
New Facet based on Instances of this Class
Attributes
Values
type
Academic Article
research paper
schema:ScholarlyArticle
isDefinedBy
Covid-on-the-Web dataset
has title
Antigen-specific oncolytic MV-based tumor vaccines through presentation of selected tumor-associated antigens on infected cells or virus-like particles
Creator
Beissert, Tim
Hutzler, Stefan
Sahin, Ugur
Boller, Klaus
Eberle, Regina
Erbar, Stephanie
Klamp, Thorsten
Bodmer, Bianca
Hanauer, Jan
Jabulowsky, Robert
Mühlebach, Michael
Schnotz, Jürgen
Source
PMC
abstract
Recombinant vaccine strain-derived measles virus (MV) is clinically tested both as vaccine platform to protect against other pathogens and as oncolytic virus for tumor treatment. To investigate the potential synergism in anti-tumoral efficacy of oncolytic and vaccine properties, we chose Ovalbumin and an ideal tumor antigen, claudin-6, for pre-clinical proof of concept. To enhance immunogenicity, both antigens were presented by retroviral virus-like particle produced in situ during MV-infection. All recombinant MV revealed normal growths, genetic stability, and proper expression and presentation of both antigens. Potent antigen-specific humoral and cellular immunity were found in immunized MV-susceptible IFNAR(−/−)-CD46Ge mice. These immune responses significantly inhibited metastasis formation or increased therapeutic efficacy compared to control MV in respective novel in vivo tumor models using syngeneic B16-hCD46/mCLDN6 murine melanoma cells. These data indicate the potential of MV to trigger selected tumor antigen-specific immune responses on top of direct tumor lysis for enhanced efficacy.
has issue date
2017-12-04
(
xsd:dateTime
)
bibo:doi
10.1038/s41598-017-16928-8
bibo:pmid
29203786
has license
cc-by
sha1sum (hex)
3ba5a8bec872feebb62f6a1f384690ba1cd63a8b
schema:url
https://doi.org/10.1038/s41598-017-16928-8
resource representing a document's title
Antigen-specific oncolytic MV-based tumor vaccines through presentation of selected tumor-associated antigens on infected cells or virus-like particles
has PubMed Central identifier
PMC5715114
has PubMed identifier
29203786
schema:publication
Sci Rep
resource representing a document's body
covid:3ba5a8bec872feebb62f6a1f384690ba1cd63a8b#body_text
is
schema:about
of
named entity 'CELLS'
named entity 'potential'
named entity 'antigens'
named entity 'concept'
named entity 'TO INVESTIGATE'
named entity 'PRESENTED'
named entity 'INHIBITED'
named entity 'ANTIGEN'
named entity 'TUMOR VACCINES'
named entity 'SPECIFIC'
named entity 'THESE'
named entity 'EFFICACY'
named entity 'MURINE'
named entity 'USING'
named entity 'COMPARED'
named entity 'CELLULAR IMMUNITY'
named entity 'PRESENTATION'
named entity 'ANTIGENS'
named entity 'INFECTED'
named entity 'TUMOR ANTIGEN'
named entity 'ANTIGEN'
named entity 'B16'
named entity 'RETROVIRAL'
named entity 'VIRUS-LIKE PARTICLES'
named entity 'PRESENTATION'
named entity 'ANTIGENS'
named entity 'ASSOCIATED'
named entity 'IFNAR'
named entity 'GROWTHS'
named entity 'IMMUNOGENICITY'
named entity 'INCREASED'
named entity 'PROPERTIES'
named entity 'DIRECT'
named entity 'IMMUNE RESPONSES'
named entity 'ENHANCED'
named entity 'ONCOLYTIC'
named entity 'LYSIS'
named entity 'PROPER'
named entity 'PRE-CLINICAL'
named entity 'FORMATION'
named entity 'IN SITU'
named entity 'RECOMBINANT'
named entity 'VIRUS-LIKE PARTICLE'
named entity 'MICE'
named entity 'TUMOR'
named entity 'CLAUDIN-6'
named entity 'THERAPEUTIC EFFICACY'
named entity 'HCD46'
named entity 'IN VIVO'
named entity 'SYNERGISM'
named entity 'INFECTION'
named entity 'FOUND'
named entity 'REVEALED'
named entity 'CHOSE'
named entity 'NORMAL'
named entity 'POTENTIAL'
named entity 'OVALBUMIN'
named entity 'PROOF OF CONCEPT'
named entity 'NOVEL'
named entity 'VACCINE'
named entity 'ENHANCE'
named entity 'GENETIC STABILITY'
named entity 'ONCOLYTIC'
named entity 'MELANOMA CELLS'
named entity 'SYNGENEIC'
named entity 'EXPRESSION'
named entity 'IDEAL'
named entity 'TUMOR MODELS'
named entity 'TRIGGER'
named entity 'TO CONTROL'
◂◂ First
◂ Prev
Next ▸
Last ▸▸
Page 1 of 15
Go
Faceted Search & Find service v1.13.91 as of Mar 24 2020
Alternative Linked Data Documents:
Sponger
|
ODE
Content Formats:
RDF
ODATA
Microdata
About
OpenLink Virtuoso
version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software